VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Jon Salmanton-García, Pauline Wipfler, Paula Valle-Simón, Christina Merakou, Ioannis Kopsidas, Ullrich Bethe, Angela Steinbach, Orly Spivak, Lenka Součková, Maria Amélia Mendonça, Markela Koniordou, Margot Hellemans, Jesus Frías-Iniesta, Ruth Joanna Davis, Imre Barta, Anna Maria Azzini, Helena H. Askling, Christos D. Argyropoulos, Elena Álvarez-Barco, Murat AkovaMarc M.J. Bonten, Miriam Cohen-Kandli, Rebecca Jane Cox, Robert Flisiak, Petr Husa, Ligita Jancoriene, Alena Koscalova, Odile Launay, Jens Lundgren, Patrick Mallon, Laura Marques, Pontus Nauclér, Jordi Ochando, Zoi Dorothea Pana, Evelina Tacconelli, Krisztina Tóth, Sven Trelle, Pierre van Damme, Theoklis E. Zaoutis, Markus Zeitlinger, Kerstin Albus, Fiona A. Stewart, Sanne H.I. Hofstraat, Patricia Bruijning-Verhagen, Oliver A. Cornely

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background: The inconsistent European vaccine trial landscape rendered the continent of limited interest for vaccine developers. The VACCELERATE consortium created a network of capable clinical trial sites throughout Europe. VACCELERATE identifies and provides access to state-of-the-art vaccine trial sites to accelerate clinical development of vaccines. Methods: Login details for the VACCELERATE Site Network ( questionnaire can be obtained after sending an email to. Interested sites provide basic information, such as contact details, affiliation with infectious disease networks, main area of expertise, previous vaccine trial experience, site infrastructure and preferred vaccine trial settings. In addition, sites can recommend other clinical researchers for registration in the network. If directly requested by a sponsor or sponsor representative, the VACCELERATE Site Network pre-selects vaccine trial sites and shares basic study characteristics provided by the sponsor. Interested sites provide feedback with short surveys and feasibility questionnaires developed by VACCELERATE and are connected with the sponsor to initiate the site selection process. Results: As of April 2023, 481 sites from 39 European countries have registered in the VACCELERATE Site Network. Of these, 137 (28.5 %) sites have previous experience conducting phase I trials, 259 (53.8 %) with phase II, 340 (70.7 %) with phase III, and 205 (42.6 %) with phase IV trials, respectively. Infectious diseases were reported as main area of expertise by 274 sites (57.0 %), followed by any kind of immunosuppression by 141 (29.3 %) sites. Numbers are super additive as sites may report clinical trial experience in several indications. Two hundred and thirty-one (47.0 %) sites have the expertise and capacity to enrol paediatric populations and 391 (79.6 %) adult populations. Since its launch in October 2020, the VACCELERATE Site Network has been used 21 times for academic and industry trials, mostly interventional studies, focusing on different pathogens such as fungi, monkeypox virus, Orthomyxoviridae/influenza viruses, SARS-CoV-2, or Streptococcus pneumoniae/pneumococcus. Conclusions: The VACCELERATE Site Network enables a constantly updated Europe-wide mapping of experienced clinical sites interested in executing vaccine trials. The network is already in use as a rapid-turnaround single contact point for the identification of vaccine trials sites in Europe.

Original languageEnglish
Pages (from-to)3915-3922
Number of pages8
Issue number26
StatePublished - 13 Jun 2023
Externally publishedYes


  • Clinical network
  • Pandemic preparedness
  • Registry
  • SARS-CoV-2
  • Site
  • Vaccine trial


Dive into the research topics of 'VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe'. Together they form a unique fingerprint.

Cite this